Journal article

Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia

Typhoid vaccination is a public health priority in developing countries where young children are greatly affected by typhoid fever. Because present vaccines are not recommended for children younger than 2 years, the Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM197) for infant immunisation. The study assesses the immunogenicity and safety of Vi-CRM197 in participants of various ages in endemic countries in south and southeast Asia.

Languages

  • English

Publication year

2014

Journal

The Lancet Infectious Diseases

Volume

2

Type

Journal article

Categories

  • Vaccines & delivery devices

Diseases

  • Typhoid

Countries

  • India
  • Pakistan
  • Philippines

Tags

  • New vaccine introduction

WHO Regions

  • Eastern Mediterranean Region
  • South-East Asia Region
  • Western Pacific Region